Dec 09, 2021 / 01:30PM GMT
Operator
Greetings, and welcome to the Aurinia Pharmaceuticals Conference Call. (Operator Instructions). As a reminder, this conference is being recorded. I would now like to turn the conference over to Peter Greenleaf, Aurinia's President and CEO. Thank you. You may begin.
Peter S. Greenleaf - Aurinia Pharmaceuticals Inc. - President, CEO & Director
Well, thank you, and I want to thank everyone for taking the time during this busy time of the year to join us. Today, we're here to announce the top line results from the conclusion of the AURORA 2 study. To remind you, AURORA 2 is a Phase III continuation study designed to assess the long-term safety and tolerability of voclosporin when added to MMF and low-dose corticosteroids for an additional 24 months following a 52-week treatment period in the original AURORA 1 trial. While there have been interim cuts of the data presented at this year's EULAR and ACR meetings, we now have key data from the completion of the study and are actually quite pleased with the results.
Today, we issued a press release with
Aurinia Pharmaceuticals Inc Announces Positive Topline Results From the AURORA 2 Continuation Study - Corporate Call Transcript
Dec 09, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers